Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 2 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

4 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Audrey Abella, 07 Aug 2018
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.

Early neoadjuvant chemotherapy response predicts survival in cervical cancer

04 Feb 2018

An early response to neoadjuvant chemotherapy (NACT) in cervical cancer patients is significantly associated with higher disease-free survival (DFS) and improved survival rates, a recent study has shown.

Researchers performed a meta-analysis of six studies involving 490 cervical cancer patients, of whom 336 were responders and 154 were nonresponders. Included studies were those that evaluated the survival of early NACT responders, and were retrieved from PubMed and Embase databases.

Pooled data from the six studies showed that nonreponders had significantly lower 1-year overall survival compared with cervical cancer patients with early response to NACT (hazard ratio [HR], 0.25; 95 percent CI, 0.10–0.58), with nonsignificant heterogeneity (p=0.882).

The trend was similar with 2-year overall survival, where early responders showed significantly better survival than nonresponders (HR, 0.28; 0.15–0.56).

The forest plot for combined DFS in the third year likewise showed that results were significantly worse for those without early response to NACT relative to early responders (HR, 0.27; 0.16–0.45). Heterogeneity was again nonsignificant (p=0.511).

The results were similar for 4-year (HR, 0.29; 0.17–0.50) and 5-year (HR, 0.33; 0.20–0.54) survival rates.

“By combining previous study results, the present study found that a short-term response was significantly associated with the long-term survival of cervical cancer patients who underwent NACT,” said researchers.

“This finding may help doctors to evaluate the survival of this group of patients and may help to determine more effective treatment methods. Future [randomized clinical trials] should be performed to validate our results and to provide clear conclusions with less bias,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 2 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

4 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Audrey Abella, 07 Aug 2018
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.